Blood pressure reduction with HMG-CoA reductase inhibitors in renal transplant recipients.BackgroundBesides lowering lipid levels, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) modulate endothelial function and decrease vascular tone. The effect of statin therapy on blood pressure has not been previously examined in renal transplant recipients.MethodsWe identified 113 stable recipients with graft survival>1 year and started on a statin ≥1 year post-transplant with no subsequent alteration in type or dose, as well as ≥6 months' follow-up post-statin introduction along with no changes in antihypertensive medication type or dosage. This “statin” group was compared to a control group matched 1:1 by age, gender, ...
International audienceHypertension is common in kidney transplantation recipients and may be difficu...
Background and Objectives. HMG-CoA reductase inhibitor (statin) therapy reduces cardiovascular risk ...
Hypertension is common in kidney transplantation recipients and may be difficult to treat. Factors p...
Blood pressure reduction with HMG-CoA reductase inhibitors in renal transplant recipients.Background...
Renal transplant recipients are at high risk of cardiovascular diseases which represent,with infecti...
Hypertension in kidney transplant recipients is a major traditional risk factor for atheroscleroti...
Hypertension is a prevalent problem in kidney transplant recipients that is known to be a tradition...
Background: Administration of HMG-CoA reductase inhibitors (statins), prior to ischemia or prior to ...
BackgroundPeople with chronic kidney disease (CKD) have higher risks of cardiovascular disease compa...
Background and Objectives. HMG-CoA reductase inhibitor (statin) therapy reduces cardiovascular risk ...
Objective: Control of hypertension (HT) can lead to regression of left ventricular mass index (LVMI)...
Hypertension is one of the most common cardiovascular co-morbidities after successful kidney transpl...
BACKGROUND: Dysglycemia and dyslipidemia are important metabolic complications of organ transplantat...
Cardiovascular morbidity, including coronary artery disease and left ventricular hypertrophy, and mo...
Abstract: Hypertension is common following renal transplantation and adversely affects graft and pa...
International audienceHypertension is common in kidney transplantation recipients and may be difficu...
Background and Objectives. HMG-CoA reductase inhibitor (statin) therapy reduces cardiovascular risk ...
Hypertension is common in kidney transplantation recipients and may be difficult to treat. Factors p...
Blood pressure reduction with HMG-CoA reductase inhibitors in renal transplant recipients.Background...
Renal transplant recipients are at high risk of cardiovascular diseases which represent,with infecti...
Hypertension in kidney transplant recipients is a major traditional risk factor for atheroscleroti...
Hypertension is a prevalent problem in kidney transplant recipients that is known to be a tradition...
Background: Administration of HMG-CoA reductase inhibitors (statins), prior to ischemia or prior to ...
BackgroundPeople with chronic kidney disease (CKD) have higher risks of cardiovascular disease compa...
Background and Objectives. HMG-CoA reductase inhibitor (statin) therapy reduces cardiovascular risk ...
Objective: Control of hypertension (HT) can lead to regression of left ventricular mass index (LVMI)...
Hypertension is one of the most common cardiovascular co-morbidities after successful kidney transpl...
BACKGROUND: Dysglycemia and dyslipidemia are important metabolic complications of organ transplantat...
Cardiovascular morbidity, including coronary artery disease and left ventricular hypertrophy, and mo...
Abstract: Hypertension is common following renal transplantation and adversely affects graft and pa...
International audienceHypertension is common in kidney transplantation recipients and may be difficu...
Background and Objectives. HMG-CoA reductase inhibitor (statin) therapy reduces cardiovascular risk ...
Hypertension is common in kidney transplantation recipients and may be difficult to treat. Factors p...